Treatment-Related Late Adverse Events in Childhood Cancer Survivors of Mexico: A Cross-Sectional Study

José Fernando Pérez-Franco, G. Hernández-Pliego, Jocelyn Jacobo-Mendoza, Vanessa Karina Martínez-Lara, L. Juárez-Villegas, P. Clark, J. L. Vargas-Neri
{"title":"Treatment-Related Late Adverse Events in Childhood Cancer Survivors of Mexico: A Cross-Sectional Study","authors":"José Fernando Pérez-Franco, G. Hernández-Pliego, Jocelyn Jacobo-Mendoza, Vanessa Karina Martínez-Lara, L. Juárez-Villegas, P. Clark, J. L. Vargas-Neri","doi":"10.3390/pharma2020015","DOIUrl":null,"url":null,"abstract":"Late adverse events (LAEs) are an important cause of illness and disability in childhood cancer survivors (CCSs) and increase the risk of mortality. The aim of this cross-sectional study was to describe the frequency and severity of treatment-related LAEs in Mexican CCSs. The study period was between September 2018 and April 2019. We tested a sample of 82 CCSs at the Hospital Infantil de México Federico Gómez. We considered an LAE to be any medical effect related to treatment after ending cancer therapy. All LAEs were classified according to severity (using the grades of Common Terminology Criteria for Adverse Events v.5.0), diagnosis and time of occurrence after treatment. The treatment-related LAE frequency was 11.0% (95% CI; 4.2–17.8%). A total of 11 LAEs were identified in nine patients. Slightly over half of the patients were male (54.9%). The most frequent diagnosis was acute lymphoblastic leukemia (45.1%). The body systems involved in LAEs were the endocrine (55.6%), neurological (22.2%), auditory (11.1%) and renal (11.1%) systems. Obesity was the most frequent LAE (45.4%). Most LAEs were classified as grade 1 and 2 (60%). The median follow-up was 6.5 years. The odds ratio was used as a measure of association to identify characteristics associated with the LAEs. We identified that the age at diagnosis (OR = 0.71, 95% CI, 0.51–0.99; p = 0.046) and chemotherapy-only group (OR = 0.03, 95% CI, 0.00–0.86, p = 0.040) were associated with LAEs. This is the first study that describes the frequency and severity of LAEs in Mexican childhood cancer survivors.","PeriodicalId":74431,"journal":{"name":"Pharmacoepidemiology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/pharma2020015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Late adverse events (LAEs) are an important cause of illness and disability in childhood cancer survivors (CCSs) and increase the risk of mortality. The aim of this cross-sectional study was to describe the frequency and severity of treatment-related LAEs in Mexican CCSs. The study period was between September 2018 and April 2019. We tested a sample of 82 CCSs at the Hospital Infantil de México Federico Gómez. We considered an LAE to be any medical effect related to treatment after ending cancer therapy. All LAEs were classified according to severity (using the grades of Common Terminology Criteria for Adverse Events v.5.0), diagnosis and time of occurrence after treatment. The treatment-related LAE frequency was 11.0% (95% CI; 4.2–17.8%). A total of 11 LAEs were identified in nine patients. Slightly over half of the patients were male (54.9%). The most frequent diagnosis was acute lymphoblastic leukemia (45.1%). The body systems involved in LAEs were the endocrine (55.6%), neurological (22.2%), auditory (11.1%) and renal (11.1%) systems. Obesity was the most frequent LAE (45.4%). Most LAEs were classified as grade 1 and 2 (60%). The median follow-up was 6.5 years. The odds ratio was used as a measure of association to identify characteristics associated with the LAEs. We identified that the age at diagnosis (OR = 0.71, 95% CI, 0.51–0.99; p = 0.046) and chemotherapy-only group (OR = 0.03, 95% CI, 0.00–0.86, p = 0.040) were associated with LAEs. This is the first study that describes the frequency and severity of LAEs in Mexican childhood cancer survivors.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
墨西哥儿童癌症幸存者与治疗相关的晚期不良事件:一项跨部门研究
晚期不良事件(LAE)是儿童癌症幸存者(CCS)患病和致残的重要原因,并增加了死亡风险。这项横断面研究的目的是描述墨西哥CCSs中与治疗相关的LAE的频率和严重程度。研究期间为2018年9月至2019年4月。我们在墨西哥步兵医院Federico Gómez测试了82个CCS样本。我们认为LAE是指癌症治疗结束后与治疗相关的任何医疗效果。根据严重程度(使用5.0版不良事件通用术语标准)、诊断和治疗后发生时间对所有LAE进行分类。与治疗相关的左心耳频率为11.0%(95%CI;4.2-17.8%)。9名患者共发现11例左心耳。略高于一半的患者是男性(54.9%)。最常见的诊断是急性淋巴细胞白血病(45.1%)。LAE涉及的身体系统是内分泌系统(55.6%)、神经系统(22.2%)、听觉系统(11.1%)和肾脏系统(11.10%)。肥胖是最常见的LAE(45.4%)。大多数LAE分为1级和2级(60%)。中位随访时间为6.5年。比值比被用作相关性的衡量标准,以确定与LAE相关的特征。我们发现,诊断时的年龄(OR=0.71,95%CI,0.51–0.99;p=0.046)和仅化疗组(OR=0.03,95%CI,0.00–0.86,p=0.040)与左心耳相关。这是第一项描述墨西哥儿童癌症幸存者LAE发生频率和严重程度的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Associations between Suspected Adverse Drug Reactions of HMG-CoA Reductase Inhibitors and Polypharmacology Using a National Registry Approach A Retrospective Analysis of the Clinical Effectiveness of Tigecycline in the Treatment of Clostridioides difficile-Associated Diarrhea Association of Receipt of Opioid Prescription for Acute Post-Delivery Pain Management with Buprenorphine Discontinuation among Postpartum People with Opioid Use Disorder Pioneering Arterial Hypertension Phenotyping on Nationally Aggregated Electronic Health Records Affordability of Paediatric Oral Anti-Infective Medicines in a Selected District, Sri Lanka
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1